SEC
CORZ icon

Seven Eight Capital’s Core Scientific CORZ Stock Holding History

Seven Eight Capital’s Portfolio CORZ Stock Details CORZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-226,363
Closed -$2.68M – 148
2024
Q3 		$2.68M Buy
+226,363
New +$2.35M 0.24% 119

Other funds holding CORZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
Gullane Capital Memphis, Tennessee $37.4M AUM 112.18% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OWP
ORG Wealth Partners Dallas, Texas $508M AUM 83.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
JCM
JAT Capital Management Greenwich, Connecticut $59.3M AUM 134.04% 1-Year Est. Return

Seven Eight Capital's CORZ Position: Q4 2024 in Review

Seven Eight Capital sold out of Core Scientific (CORZ) in Q4 2024, closing a stake of 226,363 shares — an estimated $2.68M sold.

Seven Eight Capital first reported a position in CORZ in Q3 2024 and held it in 1 quarter. The position peaked at $2.68M in Q3 2024. 313 funds tracked by Wall St. Rank hold CORZ as of Q4 2024.

  • Seven Eight Capital reported no remaining Core Scientific position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 226,363 Core Scientific shares in Q4 2024, an estimated $2.68M.
  • Seven Eight Capital first reported a position in Core Scientific in Q3 2024 and held it in 1 quarter.
  • Seven Eight Capital's Core Scientific position peaked at $2.68M in Q3 2024.
  • 313 funds tracked by Wall St. Rank held Core Scientific as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.